Movement Alert｜Novartis Rises 3.13% in Regular Trading, Positive Cosentyx Phase 3 Data Boosts Shares Amid Broad Pharma Rally

Market Focus03:22

On June 5, Novartis rose 3.13% in regular trading, trading at $148.185/share, with trading volume of $275 million. The move was driven by positive late-stage clinical trial results for its core product Cosentyx and broader strength across the pharmaceutical sector.

Novartis disclosed new Phase 3 data showing Cosentyx achieved a statistically significant and clinically meaningful difference in sustained remission rates in polymyalgia rheumatica (PMR) compared to the control group. Additionally, the company presented strong early-stage clinical data at the ASCO annual meeting for a novel radioligand therapy targeting prostate cancer, reinforcing growth expectations for its pipeline. The dual catalysts from Cosentyx and its oncology portfolio bolstered investor confidence.

Within the Pharmacy sector, the overall sector showed strength. Among individual stocks, Merck up 4.68%, Novo-Nordisk up 4.30%, Eli Lilly up 4.04%, Johnson & Johnson up 2.26%, Pfizer up 1.48%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111582137?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 03:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111582137","market":"us","top_or_hot":-1,"title":"Movement Alert｜Novartis Rises 3.13% in Regular Trading, Positive Cosentyx Phase 3 Data Boosts Shares Amid Broad Pharma Rally","media":"Market Focus","content":"<p><p>On June 5, Novartis rose 3.13% in regular trading, trading at $148.185/share, with trading volume of $275 million. The move was driven by positive late-stage clinical trial results for its core product Cosentyx and broader strength across the pharmaceutical sector.</p><p>Novartis disclosed new Phase 3 data showing Cosentyx achieved a statistically significant and clinically meaningful difference in sustained remission rates in polymyalgia rheumatica (PMR) compared to the control group. Additionally, the company presented strong early-stage clinical data at the ASCO annual meeting for a novel radioligand therapy targeting prostate cancer, reinforcing growth expectations for its pipeline. The dual catalysts from Cosentyx and its oncology portfolio bolstered investor confidence.</p><p>Within the Pharmacy sector, the overall sector showed strength. Among individual stocks, Merck up 4.68%, Novo-Nordisk up 4.30%, Eli Lilly up 4.04%, Johnson & Johnson up 2.26%, Pfizer up 1.48%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Novartis Rises 3.13% in Regular Trading, Positive Cosentyx Phase 3 Data Boosts Shares Amid Broad Pharma Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Novartis Rises 3.13% in Regular Trading, Positive Cosentyx Phase 3 Data Boosts Shares Amid Broad Pharma Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-05 03:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 5, Novartis rose 3.13% in regular trading, trading at $148.185/share, with trading volume of $275 million. The move was driven by positive late-stage clinical trial results for its core product Cosentyx and broader strength across the pharmaceutical sector.</p><p>Novartis disclosed new Phase 3 data showing Cosentyx achieved a statistically significant and clinically meaningful difference in sustained remission rates in polymyalgia rheumatica (PMR) compared to the control group. Additionally, the company presented strong early-stage clinical data at the ASCO annual meeting for a novel radioligand therapy targeting prostate cancer, reinforcing growth expectations for its pipeline. The dual catalysts from Cosentyx and its oncology portfolio bolstered investor confidence.</p><p>Within the Pharmacy sector, the overall sector showed strength. Among individual stocks, Merck up 4.68%, Novo-Nordisk up 4.30%, Eli Lilly up 4.04%, Johnson & Johnson up 2.26%, Pfizer up 1.48%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVS","symbol_name":"诺华","start_time":0,"source_url":"","article_id":"1111582137","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111582137","pubTimestamp":1780600945,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 5, Novartis rose 3.13% in regular trading, trading at $148.185/share, with trading volume of $275 million. The move was driven by positive late-stage clinical trial results for its core...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVS":"诺华"},"translate_title":"动态警报|诺华常规交易上涨3.13%，Cosentyx 3期数据利好提振股价，制药行业普遍上涨","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":1},"content_text":"On June 5, Novartis rose 3.13% in regular trading, trading at $148.185/share, with trading volume of $275 million. The move was driven by positive late-stage clinical trial results for its core product Cosentyx and broader strength across the pharmaceutical sector.Novartis disclosed new Phase 3 data showing Cosentyx achieved a statistically significant and clinically meaningful difference in sustained remission rates in polymyalgia rheumatica (PMR) compared to the control group. Additionally, the company presented strong early-stage clinical data at the ASCO annual meeting for a novel radioligand therapy targeting prostate cancer, reinforcing growth expectations for its pipeline. The dual catalysts from Cosentyx and its oncology portfolio bolstered investor confidence.Within the Pharmacy sector, the overall sector showed strength. Among individual stocks, Merck up 4.68%, Novo-Nordisk up 4.30%, Eli Lilly up 4.04%, Johnson & Johnson up 2.26%, Pfizer up 1.48%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111582137","isCrawlerRequest":true}